Roth Capital Has Bearish Estimate for CervoMed Q3 Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings per share estimate for CervoMed down to ($0.76), compared to a previous estimate of ($0.50).
• CervoMed's recent quarterly earnings report revealed a miss in analysts' estimates, posting an EPS of ($0.70) against a consensus of ($0.57).
• The company has a mixed rating from analysts, with an average rating of "Moderate Buy" and a consensus price target of $21.43.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Roth Capital cut their Q3 2025 EPS estimates for CervoMed in a note issued to investors on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their previous forecast of ($0.50). Roth Capital currently has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $1.45 million.

A number of other research firms have also recently commented on CRVO. Canaccord Genuity Group boosted their target price on shares of CervoMed from $21.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Chardan Capital reaffirmed a "buy" rating and set a $15.00 price objective on shares of CervoMed in a research note on Monday. Finally, D. Boral Capital boosted their target price on shares of CervoMed from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $21.43.

CervoMed Stock Performance

CRVO opened at $9.64 on Thursday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $20.63. The company has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.05. The stock has a market capitalization of $89.20 million, a price-to-earnings ratio of -3.69 and a beta of -0.79.

Hedge Funds Weigh In On CervoMed

Several large investors have recently made changes to their positions in CRVO. Rhumbline Advisers increased its stake in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after buying an additional 1,526 shares during the period. HighTower Advisors LLC purchased a new stake in shares of CervoMed in the 1st quarter valued at approximately $104,000. Marshall Wace LLP purchased a new stake in shares of CervoMed in the 2nd quarter valued at approximately $76,000. Bank of New York Mellon Corp purchased a new position in shares of CervoMed in the 1st quarter valued at $110,000. Finally, Mariner LLC purchased a new position in shares of CervoMed in the 4th quarter valued at $30,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.